The Picus 2 Electronic Pipette - Sartorius Stedim Biotech bets on ergonomic precision
Published on 07/26/2026 at 14:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Picus 2 Electronic Pipette sits in the hand like a slim game controller, the matte plastic slightly warm from the last test run and the tiny display glowing above your thumb as you tap through modes on the bench next to a rack of clear PCR tubes.
Electronic pipette in focus
Picus 2 Electronic Pipette is part of Sartorius pipetting solutions and takes aim at labs looking for repeatable, traceable liquid handling rather than manual feel alone. According to product manager Anna Lehtinen, the updated handle contour and lighter body are designed to cut thumb strain across long workflows.
On the official Sartorius page, Picus 2 appears as an electronic single-channel pipette with multiple programmable modes, including pipetting, reverse pipetting and multi-dispensing, aimed at volumes from low microliters up to around 1200 µl depending on the chosen model. Sartorius product details
Sartorius Stedim Biotech in the lab tools market
How pipetting systems like Picus 2 Electronic Pipette support recurring revenue and instrument ecosystems for Sartorius Stedim Biotech.
Features and lab use
Picus 2 Electronic Pipette offers electronic control over aspiration and dispensing, something lab head Markus Schneider from a midsize diagnostics lab praises because junior staff can hit target volumes without relying solely on manual timing. The instrument supports step-based pipetting protocols stored directly on the device.
Sartorius highlights an intuitive interface with a small display, navigation keys and quick-access buttons so users can jump between standard pipetting, mixing or sequential dispensing without putting the pipette down. In promotional materials, Picus 2 is paired with tips from the company’s Safetyspace line to maximise accuracy in narrow wells. Sartorius pipetting portfolio
Ergonomics and compliance
Ergonomics is a central selling point. The Picus 2 body is slim, light and designed so the thumb moves a short, straight path to trigger the piston, reducing repetitive strain for lab technicians who pipette for hours. The grip surface feels slightly textured, making it less slippery with gloved hands.
With electronic modes, Picus 2 can standardise pipetting cycles across multiple operators, supporting compliance in regulated environments such as GMP labs. Documentation emphasises features like calibration reminders and potential connectivity options to help quality managers ensure instruments stay within specified performance windows. Sartorius newsroom
Role in Sartorius portfolio and stock context
As part of Sartorius pipetting and lab products, Picus 2 Electronic Pipette sits below large bioprocess equipment but still contributes ongoing revenue through consumables like compatible tips and service. For CEO Joachim Kreuzburg, such instruments help tie customer labs more closely into Sartorius ecosystems.
On the market, Picus 2 competes with electronic pipettes from other lab brands yet aligns with Sartorius emphasis on precision bioprocess tools and life science workflows. The Sartorius Stedim Biotech share (ISIN FR0013154002) trades on Euronext Paris in euros, with pipetting systems forming a small but recurring part of the company’s broader revenue base.
Key facts on Picus 2 Electronic Pipette
- Product: Picus 2 Electronic Pipette
- Manufacturer: Sartorius Stedim Biotech SA
- Category: Classic / Longseller laboratory pipette
- Market launch: Around early 2020s, according to Sartorius product information
- MSRP / Price: Typically listed in euro pricing for European markets, varying by volume range and configuration
- Availability: Available via Sartorius sales channels and specialist lab distributors internationally
- Target group: Research, diagnostics and quality control laboratories needing ergonomic, electronic pipetting
- Highlight / USP: Electronic, programmable pipetting modes in a lightweight, ergonomically contoured body
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
